Oncternal Therapeutics Inc (OQ:ONCT)

Business Focus: Biotechnology & Medical Research

Apr 18, 2024 09:00 am ET
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the first patient has been dosed in the fourth cohort of its Phase 1/2 study of...
Mar 15, 2024 09:00 am ET
Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced it will participate in a virtual fireside chat on the Treatment Landscape & New...
Mar 07, 2024 04:01 pm ET
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported fourth quarter and full year 2023 financial results. “We...
Feb 29, 2024 04:05 pm ET
Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report fourth quarter and full year 2023 financial results after the U.S....
Feb 06, 2024 04:30 pm ET
Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that James Breitmeyer, M.D, Ph.D., Oncternal’s President and Chief Executive Officer...
Feb 01, 2024 09:00 am ET
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the approval of an inducement award to one new employee, Damien Bresson, who is joining...
Jan 08, 2024 09:00 am ET
Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the fourth patient has now been enrolled into its Phase 1/2 study of ONCT-534, its...
Jan 04, 2024 09:00 am ET
Oncternal Therapeutics Announces Reverse Stock Split
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that its board of directors (Board) has approved a 1-for-20 reverse stock split of the...
Jan 02, 2024 09:00 am ET
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the approval of an inducement award to one new employee, Rebecca Nolan-Olson, who is...
Dec 26, 2023 09:00 am ET
Oncternal Therapeutics Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-cell Lymphoma
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today updated the status of its dose escalation/dose expansion Phase 1/2 Study ONCT-808-101, evaluating...
Nov 09, 2023 04:01 pm ET
Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported third quarter 2023 financial results. “We continue to...
Nov 02, 2023 04:05 pm ET
Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report third quarter 2023 financial results after the U.S. financial...
Oct 26, 2023 09:00 am ET
Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the U.S. Food and Drug Administration (FDA) has designated ONCT-534, its novel...
Oct 25, 2023 09:00 am ET
Oncternal Therapeutics Adds Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the addition of Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory...
Oct 05, 2023 04:01 pm ET
Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of Dual-Action AR Inhibitor, ONCT-534, in Patients with Metastatic Castration-Resistant Prostate Cancer
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the first patient has been dosed in the Phase 1/2 dose escalation/dose expansion...
Sep 07, 2023 09:00 am ET
Oncternal Therapeutics Announces its Prostate Cancer Scientific Advisory Board
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the establishment of its Prostate Cancer Scientific Advisory Board (SAB). The Prostate...
Aug 10, 2023 04:01 pm ET
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2023 Financial Results
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported second quarter 2023 financial results....
Aug 03, 2023 04:30 pm ET
Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2023 financial results after the U.S. financial...
Aug 03, 2023 04:05 pm ET
Oncternal Therapeutics Receives FDA Study May Proceed Letter for ONCT-534, its Novel Dual-action Androgen Receptor Inhibitor, for the Treatment of Patients with Advanced Prostate Cancer
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the receipt of a Study May Proceed letter from the U.S. Food and Drug Administration...
Jul 26, 2023 01:30 pm ET
Northland Capital Markets Institutional Investor Conference
MINNEAPOLIS, MN / ACCESSWIRE / July 26, 2023 / We are pleased to be hosting the Northland Capital Markets Institutional Investor Conference 2023 on Tuesday September 19, 2023, at the Minneapolis Marriott City Center, Downtown Minneapolis. We have over 90 companies to participating. The format will be 10 one-on-one meetings (or small group) scheduled in 35 minute increments.
Jun 30, 2023 04:30 pm ET
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the approval of an inducement award to one new employee, Yisrael Katz, M.D. who is...
Jun 06, 2023 04:01 pm ET
Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of ROR1 targeting autologous CAR T, ONCT-808, in patients with relapsed or refractory aggressive B-cell lymphoma
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the first patient has been dosed in the Phase 1/2 dose escalation/dose expansion...
May 31, 2023 05:00 pm ET
Oncternal Therapeutics to Participate at the 2023 Jefferies Healthcare Conference
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that Dr. James Breitmeyer, Oncternal’s President and Chief Executive Officer will...
May 04, 2023 04:01 pm ET
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported first quarter 2023 financial results. “Oncternal is...
Apr 27, 2023 05:00 pm ET
Oncternal Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report first quarter 2023 financial results after the U.S. financial...
Apr 13, 2023 05:00 pm ET
Oncternal Therapeutics Participating in Oppenheimer & Co.’s Virtual Fireside Chat: Discussion of ROR1 CAR T Cell Therapy in Hematological Malignancies and Solid Tumors
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that two key industry opinion leaders and management will participate in Oppenheimer &...
Apr 03, 2023 04:01 pm ET
Oncternal Therapeutics Announces Strategic Reprioritization and Capital Preservation, Extends Cash Runway into 2025
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced a strategic reprioritization based on the rapidly changing commercial landscape for...
Mar 27, 2023 09:00 am ET
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the approval of an inducement award to one new employee, Erik S. Nelson, who joined...
Mar 09, 2023 04:01 pm ET
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2022 Financial Results
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported fourth quarter and full year 2022 financial results....
Mar 02, 2023 05:00 pm ET
Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report fourth quarter and full year 2022 financial results after the U.S....
Mar 01, 2023 05:00 pm ET
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has granted an inducement award to one new employee, Yelena Tsabur, who joined...
Feb 01, 2023 05:00 pm ET
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has granted an inducement award to one new employee, Jennifer Neumann, who...
Jan 04, 2023 04:05 pm ET
Oncternal Therapeutics Announces the Appointment of Jill DeSimone to the Board of Directors
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the appointment of Jill DeSimone to its board of directors. “We are thrilled to have...
Jan 03, 2023 05:00 pm ET
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has granted inducement awards to two new non-executive employees. The awards...
Dec 13, 2022 07:41 am ET
Thinking about buying stock in Magenta Therapeutics, Ventyx Biosciences, Wave Life Sciences, Oncternal Therapeutics, or EHang Holdings?
NEW YORK, Dec. 13, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MGTA, VTYX, WVE, ONCT, and EH.
Dec 10, 2022 03:00 pm ET
Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASH 2022
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced updated interim clinical data from ongoing Phase 1/2 Study CIRM-0001 in an oral...
Dec 01, 2022 05:00 pm ET
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has granted an inducement award to one new employee, James Robinson, who joined...
Nov 14, 2022 05:00 pm ET
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has granted an inducement award to one new employee, Edward C. Dow, who joined...
Nov 03, 2022 04:01 pm ET
Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2022 Financial Results
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported financial results for the third quarter of 2022. “This...
Nov 03, 2022 09:05 am ET
Oncternal Therapeutics to Present Updated Interim Phase 1/2 Data for Zilovertamab in Combination with Ibrutinib in an Oral Session at ASH 2022
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that interim clinical data from the ongoing Phase 1/2 Study CIRM-0001 will be presented...
Oct 27, 2022 05:53 pm ET
Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report third quarter 2022 financial results after the U.S. financial...
Oct 03, 2022 05:30 pm ET
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has granted an inducement award to one new employee, Ariadne Jerue, who joined...
Oct 03, 2022 04:31 pm ET
Oncternal Therapeutics Receives IND Clearance for ONCT-808, its autologous CAR T Product Candidate Targeting ROR1 for the Treatment of Aggressive B Cell Lymphoma
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the receipt of a ‘Study May Proceed’ letter from the U.S. Food and Drug Administration...
Sep 27, 2022 09:00 am ET
Oncternal Therapeutics Initiates Global Registrational Phase 3 Study of Zilovertamab for Patients with MCL
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the initiation of its Phase 3 global registrational study of zilovertamab, ZILO-301...
Sep 23, 2022 09:00 am ET
Oncternal Therapeutics to Participate in the Cantor Oncology, Hematology & HemeOnc Conference
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will participate in the Cantor Oncology, Hematology & HemeOnc Conference...
Sep 13, 2022 09:31 am ET
Thinking about buying stock in Core & Main, Catalyst Pharmaceuticals, Ironsource, Clovis Oncology, or Oncternal Therapeutics?
NEW YORK, Sept. 13, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CNM, CPRX, IS, CLVS, and ONCT.
Sep 07, 2022 05:00 pm ET
Oncternal Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will participate in the H.C. Wainwright 24th Annual Global Investment...
Aug 09, 2022 04:05 pm ET
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2022 Financial Results
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported financial results for the second quarter of 2022. “The...
Aug 02, 2022 05:00 pm ET
Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2022 financial results after the U.S. financial...
Jul 14, 2022 04:01 pm ET
Oncternal Therapeutics Announces Clinical Trial Collaboration to Advance Zilovertamab Phase 3 Study in combination with Ibrutinib for Patients with MCL
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced it entered into a clinical trial collaboration with Pharmacyclics, an AbbVie company,...
Jun 13, 2022 08:30 am ET
Thinking about buying stock in Redbox, New Oriental Education, Day One Biopharmaceuticals, Exicure, or Oncternal Therapeutics?
NEW YORK, June 13, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RDBX, EDU, DAWN, XCUR, and ONCT.
Jun 10, 2022 04:30 pm ET
Oncternal Therapeutics Presents New Preclinical Data from its anti-ROR1 Cell Therapy Collaboration with the Karolinska Institutet at the EHA2022 Congress
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that preclinical data from its ROR1-targeting cell therapy programs will be highlighted...
Jun 10, 2022 09:00 am ET
Oncternal Therapeutics Presents Rationale and Plans for its Registrational Phase 3 Study Evaluating Zilovertamab in Combination with Ibrutinib at the EHA 2022 Congress
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the rationale and plans for its upcoming Phase 3 ZILO-301 (zilovertamab plus...
Jun 03, 2022 08:30 am ET
Thinking about buying stock in Energy Focus, Oncternal Therapeutics, StoneCo, Redbox, or TOMI Environmental Solutions?
NEW YORK, June 3, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EFOI, ONCT, STNE, RDBX, and TOMZ.
Jun 02, 2022 09:00 am ET
Oncternal Therapeutics to Participate in the Jefferies Healthcare Conference 2022
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will participate in the Jefferies Healthcare Conference being held June...
Jun 01, 2022 05:00 pm ET
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has granted an inducement award to one new employee, Ted Shih, who joined the...
May 26, 2022 05:15 pm ET
Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASCO 2022
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced updated interim clinical data from the ongoing Phase 1/2 CIRLL (Cirmtuzumab and...
May 05, 2022 04:01 pm ET
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2022 Financial Results
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported financial results for the first quarter of 2022. “In the...
May 02, 2022 05:00 pm ET
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has granted an inducement award to one new employee, Samantha Carrington, who...
Apr 28, 2022 05:00 pm ET
Oncternal Therapeutics to Provide Business Update and Report First Quarter 2022 Financial Results
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report first quarter 2022 financial results after the U.S. financial...
Apr 13, 2022 08:30 am ET
Oncternal Therapeutics Deprioritizes Development of ONCT-216 to Focus Resources on Phase 3 Trial for Zilovertamab in the Treatment of Mantle Cell Lymphoma
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has deprioritized further development of ONCT-216 to reallocate resources to...
Apr 01, 2022 05:00 pm ET
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has granted an inducement award to one new employee, Rachel Monet Kenny, who...
Mar 10, 2022 04:01 pm ET
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2021 Financial Results
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported fourth quarter and full year 2021 financial results....
Mar 07, 2022 05:00 pm ET
Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2021 Financial Results
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report fourth quarter and full year 2021 financial results after the U.S....
Mar 01, 2022 05:00 pm ET
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has granted an inducement award to one new employee, Susette Gorak, who joined...
Jan 20, 2022 04:05 pm ET
Oncternal Therapeutics Hosting Key Opinion Leader Webinar on Hematological Malignancies and Prostate Cancer
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will host a key opinion leader (KOL) webinar on hematological malignancies and...
Jan 04, 2022 04:01 pm ET
Oncternal Therapeutics Announces Agreement with U.S. FDA on Phase 3 Registrational Study Design for Zilovertamab in the Treatment of Mantle Cell Lymphoma
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that following a successful End-of-Phase 2 meeting with the U.S. Food and Drug...
Dec 13, 2021 08:00 am ET
Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASH 2021
Updated mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) data from the CIRLL study are encouraging, and comparable to previous results presented at ASCO 2021Objective response rate (ORR) of 81% (21 of 26 evaluable patients) observed...
Dec 01, 2021 05:00 pm ET
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has granted an inducement award to one new employee, Carina Freedman, who joined...
Nov 15, 2021 08:00 am ET
Oncternal Therapeutics Presented Updated Interim Phase 1/2 Clinical Trial Data for ONCT-216 in Patients with Relapsed/Refractory Ewing Sarcoma at CTOS 2021 Virtual Annual Meeting
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced updated interim clinical data from the Phase 2 expansion cohort of its ongoing Phase 1/2...
Nov 09, 2021 05:00 pm ET
Oncternal Therapeutics to Present at the 12th Annual Jefferies London Healthcare Conference
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will present and participate virtually at the 12th Annual Jefferies...
Nov 04, 2021 04:05 pm ET
Oncternal Provides Business Update and Announces Third Quarter 2021 Financial Results
expressing tumors SAN DIEGO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today reported financial results for...
Nov 03, 2021 05:00 pm ET
Oncternal Therapeutics Joins Karolinska Institutet’s NextGenNK Competence Center for the Development of Next Generation NK Cell-Based Cancer Immunotherapies
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced it has joined Karolinska Institutet’s NextGenNK Competence Center for the Development of...
Nov 02, 2021 05:00 pm ET
Oncternal Therapeutics Announces Formation of Cell Therapy Scientific Advisory Board
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the establishment of its Cell Therapy Scientific Advisory Board (SAB). The Cell Therapy...
Nov 01, 2021 04:05 pm ET
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has granted an inducement award to one new employee, Mohab Hassanin, who joined...
Oct 29, 2021 08:00 am ET
Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2021 Financial Results
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report third quarter 2021 financial results after the U.S. financial...
Oct 05, 2021 04:05 pm ET
Oncternal Therapeutics Announced Pre-Clinical Data from ONCT-534, an Androgen Receptor N-Terminal-Domain-Binding Small Molecule Degrader, Was Accepted for Virtual Poster Presentation at AACR-NCI-EORTC
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced pre-clinical data from ONCT-534, an androgen receptor N-terminal-domain-binding small...
Oct 01, 2021 04:01 pm ET
Oncternal Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has granted inducement awards to Emily Samec, who joined the Company as Vice...
Sep 20, 2021 08:00 am ET
Celularity and Oncternal Therapeutics Enter into Research Collaboration to Evaluate Targeted Placental-Derived Cellular Therapies
Celularity Inc. (“Celularity”) (Nasdaq: CELU), a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic therapies, and Oncternal Therapeutics, Inc. (“Oncternal”) (Nasdaq: ONCT), a clinical-stage biopharmaceutical...
Sep 20, 2021 08:00 am ET
Oncternal Therapeutics and Celularity Enter into Research Collaboration to Evaluate Targeted Placental-Derived Cellular Therapies
Oncternal Therapeutics, Inc. (“Oncternal”) (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, and Celularity Inc. (“Celularity”) (Nasdaq: CELU), a clinical-stage biotechnology company...
Sep 09, 2021 04:01 pm ET
Oncternal Therapeutics to Participate in September Investor Conferences
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will participate in the following conferences in the month of September:...
Sep 01, 2021 04:01 pm ET
Oncternal Therapeutics Rounds Out Leadership Team with Appointment of Steven Hamburger, Ph.D. as Senior Vice President, Regulatory Affairs and Quality Assurance
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the appointment of Steven Hamburger, Ph.D. as Senior Vice President of Regulatory...
Aug 05, 2021 04:01 pm ET
Oncternal Provides Business Update and Announces Second Quarter 2021 Financial Results
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today reported financial results for the second quarter of 2021. Oncternal management will host a...
Aug 02, 2021 04:05 pm ET
Oncternal Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has granted inducement awards to two new non-executive employees. The awards...
Aug 02, 2021 04:04 pm ET
Oncternal Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
Oncternal Therapeutics (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will participate in the BTIG Virtual Biotechnology Conference being held...
Jul 29, 2021 08:00 am ET
Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2021 Financial Results
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2021 financial results after the U.S. financial...
Jul 01, 2021 04:05 pm ET
Oncternal Therapeutics Appoints Pablo Urbaneja as Sr. Vice President, Corporate Development
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the appointment of Pablo Urbaneja as Senior Vice President, Corporate Development. Mr....
Jun 01, 2021 04:05 pm ET
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has granted an inducement award to one new employee, Christopher Markey, who...
May 26, 2021 08:00 am ET
Oncternal Therapeutics to Participate in Jefferies Virtual Healthcare Conference
Oncternal Therapeutics (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will present a corporate overview at the Jefferies Virtual Healthcare...
May 19, 2021 05:30 pm ET
Oncternal Therapeutics Presents Updated Interim Data for TK216 in Patients with Relapsed or Refractory Ewing Sarcoma in an Oral Session at ASCO 2021
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced updated interim clinical data from the oral presentation on its ongoing Phase 1/2...
May 19, 2021 05:01 pm ET
Oncternal Therapeutics Presents Updated Interim Data for Cirmtuzumab in Combination with Ibrutinib at ASCO 2021
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced updated interim clinical data, from the ongoing Phase 1/2 CIRLL (Cirmtuzumab and...
May 17, 2021 04:01 pm ET
Oncternal Therapeutics Announces Appointment of Salim Yazji as Chief Medical Officer
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the appointment of industry veteran Salim Yazji, M.D., as Chief Medical Officer....
May 06, 2021 04:01 pm ET
Oncternal Provides Business Update and Announces First Quarter 2021 Financial Results
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today reported financial results for the first quarter of 2021. Oncternal management will host a webcast...
May 03, 2021 04:01 pm ET
Oncternal Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has granted inducement awards to two new non-executive employees. The awards...
Apr 29, 2021 04:01 pm ET
Oncternal Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report first quarter 2021 financial results after the U.S. financial...
Apr 28, 2021 10:00 am ET
Oncternal Therapeutics Announces Presentation of Two Abstracts at ASCO 2021 Virtual Meeting
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the presentation of two abstracts at the American Society of Clinical Oncology (ASCO)...
Apr 12, 2021 04:41 pm ET
Oncternal Therapeutics Announces Appointment of Chase Leavitt as General Counsel
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the appointment of Chase Leavitt as General Counsel. Mr. Leavitt joins the Company with...
Apr 12, 2021 07:00 am ET
Oncternal Therapeutics Announces Presentation of Three Posters at AACR 2021 Virtual Meeting
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the presentation of three posters at the American Association for Cancer Research (AACR)...
Mar 18, 2021 04:38 pm ET
Oncternal Therapeutics Reports Granting of an Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has granted an inducement award to one new employee, Anita Wiseth, who joined...
Mar 11, 2021 04:01 pm ET
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2020 Financial Results
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported fourth quarter and full year 2020 financial results....
Mar 04, 2021 08:00 am ET
Oncternal Therapeutics to Report Fourth Quarter 2020 Financial Results and Provide Business Update
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report fourth quarter and full year 2020 financial results after the U.S....
Feb 24, 2021 08:00 am ET
Oncternal Therapeutics to Participate in March Investor Conferences
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will participate in the following conferences in the month of March and...
Feb 22, 2021 05:33 pm ET
Oncternal Therapeutics Reports Granting of an Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has granted an inducement award to one new non-executive employee, Christy...
Jan 28, 2021 04:01 pm ET
Oncternal Therapeutics Announces the Appointment of Dr. Rosemary Mazanet to the Board of Directors
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the appointment of Rosemary Mazanet, M.D., Ph.D., to its Board of Directors, effective...
Jan 14, 2021 08:00 am ET
Oncternal Therapeutics, Inc. Confirms Lentigen Technology, Inc. to Manufacture Lentiviral Vectors for Its ROR1-targeting CAR-T Cell Therapy Program
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced an agreement with Lentigen Technology, Inc. (“Lentigen”), a wholly-owned subsidiary of...
Jan 07, 2021 04:01 pm ET
Oncternal Therapeutics and Karolinska Institutet Establish Collaboration for Research and Development of ROR1-targeting CAR-T and CAR-NK Cell Therapies
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it established a research and development collaboration with world-renowned...
Jan 05, 2021 08:00 am ET
Oncternal Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect 2021 Conference
Oncternal Therapeutics (Nasdaq: ONCT), today announced that James Breitmeyer, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat hosted by H.C. Wainwright on Monday, January 11, 2021. The discussion may cover...
Dec 14, 2020 04:01 pm ET
Oncternal Therapeutics Announces Closing of $86.2 Million Bought Deal and Full Exercise of Option to Purchase Additional Shares
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the closing of its previously announced public offering on a firm commitment basis of...
Dec 10, 2020 09:50 am ET
Thinking about buying stock in Neos Therapeutics, Oncternal Therapeutics, Heat Biologics, FuelCell Energy, or Cinedigm Corp?
NEW YORK, Dec. 10, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NEOS, ONCT, HTBX, FCEL, and CIDM.
Dec 09, 2020 11:50 pm ET
Oncternal Therapeutics Increases Previously Announced Bought Deal to $75.0 Million
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that due to demand, the underwriter has agreed to increase the size of the previously...
Dec 09, 2020 06:07 pm ET
Oncternal Therapeutics Announces $40.0 Million Bought Deal Offering
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under...
Dec 07, 2020 08:00 am ET
Oncternal Therapeutics Announces Presentation of Interim Phase 1/2 Data Update for Cirmtuzumab in Combination with Ibrutinib at ASH 2020 Virtual Annual Meeting
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced updated interim clinical data from the ongoing Phase 1/2 CIRLL (Cirmtuzumab and...
Dec 07, 2020 07:30 am ET
Thinking about buying stock in Pfizer, Moderna, Oncternal Therapeutics, Fate Therapeutics, or Atara Biotherapeutics?
NEW YORK, Dec. 7, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PFE, MRNA, ONCT, FATE, and ATRA.
Nov 17, 2020 11:00 pm ET
Oncternal Therapeutics Increases Previously Announced Bought Deal to $22.5 Million
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that due to demand, the underwriter has agreed to increase the size of the previously...
Nov 17, 2020 05:27 pm ET
Oncternal Therapeutics Announces $20.0 Million Bought Deal Offering
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under...
Nov 11, 2020 08:00 am ET
Oncternal Therapeutics Announces Presentation of Interim Phase 1 Clinical Trial Data for TK216 in Patients with Relapsed/Refractory Ewing Sarcoma at CTOS 2020 Virtual Annual Meeting
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced updated interim clinical data from its ongoing Phase 1 clinical trial evaluating TK216,...
Nov 09, 2020 04:01 pm ET
Oncternal Therapeutics to Present at Stifel Virtual Healthcare Conference
Oncternal Therapeutics (Nasdaq: ONCT), today announced that James Breitmeyer, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the Stifel Virtual Healthcare Conference on Monday, November 16, 2020 at 2:00 p.m....
Nov 04, 2020 05:15 pm ET
Oncternal Announces Third Quarter 2020 Financial Results and Provides Business Update
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported third quarter 2020 financial results. “In the third...
Oct 06, 2020 08:00 am ET
Oncternal Therapeutics Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for TK216 for Treatment of Ewing Sarcoma
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation for TK216, an investigational potentially first-in-class targeted small-molecule inhibitor of the E26 transformation-specific (ETS) family of oncoproteins, for treatment of Ewing sarcoma.
Sep 22, 2020 07:00 am ET
Milestone Pharmaceuticals Strengthens Board of Directors with Two New Appointments
MONTREAL and CHARLOTTE, N.C., Sept. 22, 2020 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of Lisa Giles and Robert Wills to its Board of Directors, effective October 1, 2020. Ms. Giles will serve as a member of the Audit Committee of the Board and Dr. Wills will serve as a member of the Nominating & Corporate Governance Committee of the Board. 
Sep 21, 2020 08:00 am ET
Oncternal Therapeutics Announces Presentation of Interim Phase 1 Clinical Trial Data for TK216 in Patients with Relapsed/Refractory Ewing Sarcoma at ESMO Virtual Congress 2020
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the presentation of interim clinical data from its ongoing Phase 1 clinical trial evaluating TK216, an investigational, potentially first-in-class, targeted small-molecule inhibitor of the E26 transformation-specific (ETS) family of oncoproteins, in patients with relapsed or refractory Ewing sarcoma. Joseph A Ludwig, M.D., Associate Professor in the Department of Sarcoma Medical Oncology at The University of Texas MD Anderson Cancer Cen
Sep 10, 2020 08:00 am ET
Oncternal Therapeutics to Participate in September Investor Conferences
Oncternal Therapeutics (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will participate in the following conferences in the month of September and invites investors to join by webcast. Please see additional details below:
Aug 27, 2020 09:18 pm ET
Oncternal Therapeutics Increases Previously Announced Bought Deal to $4.5 Million
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 2,142,858 shares of common stock of the Company, at a price to the public of $2.10 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about September 1, 2020, subject to satisfaction of customary closing conditions.
Aug 27, 2020 05:18 pm ET
Oncternal Therapeutics Announces $3.5 Million Bought Deal Offering
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 1,666,667 shares of common stock of the Company, at a price to the public of $2.10 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about September 1, 2020, subject to satisfaction of customary closing conditions.
Aug 06, 2020 04:15 pm ET
Oncternal Provides Business Update and Announces Second Quarter 2020 Financial Results
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported second quarter 2020 financial results.
Jul 30, 2020 08:00 am ET
Oncternal Therapeutics to Report Second Quarter 2020 Financial Results and Provide Business Update
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2020 financial results after U.S. financial markets close on Thursday, August 6, 2020. Oncternal’s management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the Company’s financial results and provide a comprehensive business update.
Jul 27, 2020 08:00 am ET
Oncternal Therapeutics to Host Call on Cirmtuzumab and the Current Treatment Landscape for Mantle Cell Lymphoma
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will host a call with a key opinion leader (KOL) and members of the Oncternal management team to discuss the current treatment landscape of mantle cell lymphoma (MCL) and updates on the use of cirmtuzumab to treat patients with MCL on Wednesday, July 29, 2020 at 1:30 p.m. Eastern Time.
Jul 20, 2020 08:00 am ET
Oncternal Therapeutics Announces $6.2 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has entered into definitive agreements with existing institutional investors and other accredited investors, for the purchase and sale of 2,581,867 shares of its common stock, at a purchase price of $2.3825 per share, in a registered direct offering priced at-the-market under Nasdaq rules. Oncternal also agreed to issue to the investors, in a concurrent private placement, unregistered warrants to purchase up to an aggregate of 1
Jun 30, 2020 08:00 am ET
Oncternal Therapeutics Announces Orphan Drug Designations of Cirmtuzumab ROR1 Antibody for Treatment of Mantle Cell Lymphoma and for Treatment of Chronic Lymphocytic Leukemia
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the United States Food and Drug Administration (FDA) has granted the company orphan drug designations of cirmtuzumab for treatment of mantle cell lymphoma (MCL) and for treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL). Cirmtuzumab is an investigational anti-ROR1 monoclonal antibody being evaluated in clinical trials in patients with MCL, CLL and HER2-negative breast cancer.
Jun 30, 2020 07:45 am ET
Oncternal Therapeutics Announces Increased Focus of the Cirmtuzumab ROR1 Antibody Program on Mantle Cell Lymphoma
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced an updated clinical strategy for its investigational ROR1 monoclonal antibody, cirmtuzumab, that prioritizes development in mantle cell lymphoma (MCL), based on encouraging interim clinical results from the ongoing Cirmtuzumab and Ibrutinib targeting ROR1 for Leukemia and Lymphoma (CIRLL) Phase 1/2 clinical trial that were presented at the American Society of Clinical Oncology 2020 Annual Meeting (ASCO 2020) in May 2020.
May 20, 2020 08:00 am ET
Oncternal Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 1,943,636 shares of its common stock, at a purchase price of $2.5725 per share, in a registered direct offering priced at-the-market under Nasdaq rules. Oncternal has also agreed to issue to the investors, in a concurrent private placement, unregistered warrants to purchase up to an aggregate of 971,818 shares
May 19, 2020 08:00 am ET
Oncternal Therapeutics Announces Presentation of Update on Phase 1/2 Clinical Trial of Cirmtuzumab in Combination with Ibrutinib at 2020 ASCO Annual Meeting
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced updated interim clinical data from the ongoing Phase 1/2 CIRLL (Cirmtuzumab and Ibrutinib targeting ROR1 for Leukemia and Lymphoma) clinical trial, in which cirmtuzumab, an investigational anti-ROR1 monoclonal antibody, is being evaluated in combination with ibrutinib in patients with mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL). The data will be presented as part of the American Society of Clinical Oncology (ASCO) 2
May 07, 2020 08:00 am ET
Oncternal Provides Business Update and Announces First Quarter 2020 Financial Results
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported first quarter 2020 financial results.
May 05, 2020 08:00 am ET
Oncternal Therapeutics to Report First Quarter 2020 Financial Results and Provide Business Update
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report first quarter 2020 financial results before U.S. financial markets open on Thursday, May 7, 2020. Oncternal’s management will host a webcast and conference call at 12:00 p.m. PDT (3:00 p.m. EDT) to discuss the Company’s financial results and provide a comprehensive business update. The time of the webcast has been changed due to the unusually high demand for conferencing services on this date.
May 01, 2020 08:00 am ET
Oncternal Therapeutics to Report First Quarter 2020 Financial Results and Provide Business Update
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report first quarter 2020 financial results after the U.S. financial markets close on Thursday, May 7, 2020. Oncternal’s management will host a webcast and conference call at 2:00 p.m. PDT (5:00 p.m. EDT) to discuss the Company’s financial results and provide a comprehensive business update.
Mar 16, 2020 04:05 pm ET
Oncternal Provides Business Update and Announces Fourth Quarter and Full Year 2019 Financial Results
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported fourth quarter and full year 2019 financial results.
Mar 11, 2020 04:08 pm ET
Oncternal Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Business Update
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report its fourth quarter and full year 2019 financial results on March 16, 2020. Oncternal’s management will host a webcast and conference call at 1:30 p.m. PT (4:30 p.m. ET) to discuss the Company’s financial results and provide a comprehensive business update.
Mar 11, 2020 08:00 am ET
Oncternal Therapeutics Announces Interim Clinical Data Update, Including 50% Complete Response Rate, for Cirmtuzumab in Combination with Ibrutinib in Patients with Mantle Cell Lymphoma
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced an interim clinical data update for cirmtuzumab, a ROR1-targeted monoclonal antibody, combined with ibrutinib, in patients with relapsed/refractory mantle cell lymphoma (MCL) as part of the ongoing Phase 1/2 CIRLL (Cirmtuzumab and Ibrutinib targeting ROR1 for Leukemia and Lymphoma) clinical trial (data cutoff as of March 6, 2020):
Feb 06, 2020 08:00 am ET
Oncternal Therapeutics Announces Presentation of ROR1 CAR-T Preclinical Data at 2020 ASCO-SITC Clinical Immuno-Oncology Symposium
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the presentation of preclinical data from its ROR1 chimeric antigen receptor T cell (CAR-T) program at the American Society of Clinical Oncology (ASCO) – Society for Immunotherapy of Cancer (SITC) meeting in Orlando, Florida. A copy of the poster presentation is available online at
Dec 12, 2019 06:00 pm ET
Oncternal Therapeutics Announces Presentation of Interim Clinical Data on Cirmtuzumab in Combination with Paclitaxel at 2019 San Antonio Breast Cancer Symposium
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the presentation of interim data from the ongoing, investigator-sponsored Phase 1b clinical study of cirmtuzumab, its investigational anti-ROR1 monoclonal antibody, in combination with paclitaxel in patients with HER2-negative, metastatic or locally-advanced unresectable breast cancer. The results were presented at the San Antonio Breast Cancer Symposium (SABCS) in San Antonio, TX. A copy of the poster presentation is available online a
Dec 11, 2019 08:00 am ET
Oncternal Therapeutics Announces Opening of Phase 1b Expansion Cohort of Clinical Trial of TK216, Targeted ETS Inhibitor, in Patients with Ewing Sarcoma
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has opened for enrollment a Phase 1b expansion cohort of its ongoing clinical trial evaluating TK216, a first-in-class, targeted, investigational small-molecule inhibitor of the E26 transformation-specific (ETS) family of oncoproteins, in patients with relapsed or refractory Ewing sarcoma.
Dec 09, 2019 08:00 am ET
Oncternal Therapeutics Announces Presentation of Clinical Data Update on Cirmtuzumab in Combination with Ibrutinib at 2019 ASH Annual Meeting
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the presentation of updated interim clinical data from the ongoing Phase 1/2 CIRLL (Cirmtuzumab and Ibrutinib targeting ROR1 for Leukemia and Lymphoma) clinical trial, in which cirmtuzumab, an investigational anti-ROR1 monoclonal antibody, is being evaluated in combination with ibrutinib in patients with chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL). The results were presented at the American Society of Hematology (AS
Dec 03, 2019 08:00 am ET
Oncternal Therapeutics to Present Cirmtuzumab Clinical Data Updates at 2019 ASH Annual Meeting and San Antonio Breast Cancer Symposium
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that clinical data updates for cirmtuzumab, its investigational anti-ROR1 monoclonal antibody, will be presented at upcoming medical conferences.
Nov 21, 2019 08:00 am ET
Oncternal Therapeutics to Present at Piper Jaffray Healthcare Conference
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that James Breitmeyer, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the Piper Jaffray 31st Annual Healthcare Conference in New York City on Thursday, December 5, 2019 at 11:50 a.m. ET / 8:50 a.m. PT.
Nov 14, 2019 04:02 pm ET
Oncternal Therapeutics Announces Presentation of Interim Clinical Data on TK216, its First-in-class, Targeted ETS Inhibitor, in Patients with Relapsed or Refractory Ewing Sarcoma at the CTOS 2019 Annu
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the presentation of interim clinical data from its ongoing Phase 1 clinical trial evaluating TK216, a first-in-class, targeted, investigational small-molecule inhibitor of the E26 transformation-specific (ETS) family of oncoproteins, in patients with relapsed or refractory Ewing sarcoma. Paul A. Meyers, M.D., Chief, Pediatric Sarcoma Service and Vice Chair for Clinical Affairs of Memorial Sloan Kettering Cancer Center, reported at the C
Nov 11, 2019 08:00 am ET
Oncternal Therapeutics to Present at Stifel Healthcare Conference
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that James Breitmeyer, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the Stifel 2019 Healthcare Conference in New York City on Tuesday, November 19, 2019 at 10:20 a.m. ET / 7:20 a.m. PT.
Nov 07, 2019 04:05 pm ET
Oncternal Reports Third Quarter 2019 Financial Results and Provides Business Update
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced financial results for the third quarter ended September 30, 2019, and provided a business update.
Nov 05, 2019 08:00 am ET
Oncternal Therapeutics Announces Interim Clinical Data on TK216 in Ewing Sarcoma to Be Presented at the CTOS 2019 Annual Meeting
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that interim data on TK216 – an investigational targeted small molecule inhibitor of ETS transcription factor oncoproteins – will be presented at the Connective Tissue Oncology Society (CTOS) 2019 Annual Meeting in Tokyo, Japan, on November 16, 2019. The oral presentation (abstract 3250355) titled “A Phase 1 Dose Escalation Study of Intravenous TK216 in Patients with Relapsed or Refractory Ewing Sarcoma” will be given by Paul A. Meyers,
Oct 31, 2019 08:00 am ET
Oncternal Therapeutics to Report Third Quarter 2019 Financial Results and Provide Business Update
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report third quarter 2019 financial results after the U.S. financial markets close on Thursday, November 7, 2019. Oncternal’s management will host a webcast and conference call at 2:00 p.m. PST (5:00 p.m. EST) to discuss the Company’s financial results and provide a comprehensive business update.
Oct 03, 2019 08:00 am ET
Oncternal Therapeutics Announces Opening of Phase 1b Expansion Cohort of Clinical Trial of Cirmtuzumab in Combination with Ibrutinib in Patients with Mantle Cell Lymphoma
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has opened for enrollment a Phase 1b expansion cohort of its Phase 1/2 clinical trial of cirmtuzumab, a ROR1-targeted monoclonal antibody, combined with ibrutinib, in patients with mantle cell lymphoma (MCL). The decision to open an expansion cohort in MCL of the ongoing Phase 1/2 CIRLL (Cirmtuzumab and Ibrutinib targeting ROR1 for Leukemia and Lymphoma) clinical trial was based on favorable interim results from the dose-finding
Sep 17, 2019 04:05 pm ET
Oncternal Therapeutics Announces Presentation of Case Study of TK216 in Ewing Sarcoma Given at the Children’s Oncology Group Meeting
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that Paul A. Meyers, M.D., Chief, Pediatric Sarcoma Service and Vice Chair for Clinical Affairs of Memorial Sloan Kettering Cancer Center, presented a case study of a patient with Ewing sarcoma who achieved a sustained response following treatment with Oncternal’s investigational product candidate, TK216, in an ongoing Phase 1, first-in-human clinical trial. The presentation entitled, “TK216 for the Treatment of Ewing Sarcoma,” was give
Sep 09, 2019 08:00 am ET
Oncternal Further Expands Executive Team; Appoints Gunnar Kaufmann, Ph.D., as Chief Scientific Officer and Igor Bilinsky, Ph.D., as Chief Business Officer
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biotechnology company developing potential first-in-class product candidates for cancers with critical unmet medical needs, today announced the appointment of Gunnar Kaufmann, Ph.D., as Chief Scientific Officer and Igor Bilinsky, Ph.D., as Chief Business Officer.
Aug 28, 2019 04:01 pm ET
Oncternal Expands Leadership Team with Appointment of Frank Hsu, M.D., as Chief Medical Officer, and Rajesh Krishnan, Ph.D., as Senior VP CMC and Manufacturing
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biotechnology company developing potential first-in-class product candidates for cancers with critical unmet medical needs, today announced the appointment of Frank Hsu, M.D., as Chief Medical Officer, and Rajesh Krishnan, Ph.D., as Senior Vice President, Chemistry, Manufacturing and Controls (CMC) and Manufacturing.
Aug 08, 2019 04:01 pm ET
Oncternal Reports Second Quarter 2019 Financial Results and Provides Business Update
Interim objective response rate of 100% in evaluable patients with CLL receiving the recommended dosing regimen of cirmtuzumab + ibrutinib supports opening Phase 2Two product candidates moving forward in clinical trialsConference call today at 5:00...
Aug 06, 2019 08:00 am ET
Oncternal Therapeutics Announces Opening of Randomized Phase 2 Study of Cirmtuzumab in Combination with Ibrutinib
Oncternal Therapeutics, Inc., (Nasdaq: ONCT) a clinical-stage biotechnology company developing potential first-in-class product candidates for cancers with critical unmet medical need, today announced that it has opened for enrollment its...
Aug 01, 2019 04:01 pm ET
Oncternal Therapeutics to Report Second Quarter 2019 Financial Results and Provide Business Update
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biotechnology company developing potential first-in-class product candidates for cancers with critical unmet medical need, today announced that it will report second quarter 2019...
Jun 10, 2019 08:00 am ET
Oncternal Therapeutics Completes Reverse Merger with GTx, Inc.
Oncternal Therapeutics, Inc., (Nasdaq: ONCT) a clinical-stage biotechnology company developing potential first-in-class product candidates for cancers with critical unmet medical need, today announced that the reverse merger with GTx, Inc., closed...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.